ATE554769T1 - Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon - Google Patents

Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon

Info

Publication number
ATE554769T1
ATE554769T1 AT07862551T AT07862551T ATE554769T1 AT E554769 T1 ATE554769 T1 AT E554769T1 AT 07862551 T AT07862551 T AT 07862551T AT 07862551 T AT07862551 T AT 07862551T AT E554769 T1 ATE554769 T1 AT E554769T1
Authority
AT
Austria
Prior art keywords
advon
antagonists
medium
neuromuscular blockers
during neuromuscular
Prior art date
Application number
AT07862551T
Other languages
German (de)
English (en)
Inventor
John J Savarese
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of ATE554769T1 publication Critical patent/ATE554769T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07862551T 2006-12-06 2007-12-05 Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon ATE554769T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87313206P 2006-12-06 2006-12-06
PCT/US2007/024914 WO2008070121A1 (en) 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof

Publications (1)

Publication Number Publication Date
ATE554769T1 true ATE554769T1 (de) 2012-05-15

Family

ID=39492558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07862551T ATE554769T1 (de) 2006-12-06 2007-12-05 Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon

Country Status (8)

Country Link
US (1) US8148398B2 (OSRAM)
EP (1) EP2101772B1 (OSRAM)
JP (1) JP5213137B2 (OSRAM)
CN (1) CN101588803B (OSRAM)
AT (1) ATE554769T1 (OSRAM)
AU (1) AU2007328210B2 (OSRAM)
CA (1) CA2671904C (OSRAM)
WO (1) WO2008070121A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101772B1 (en) 2006-12-06 2012-04-25 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
AU2008222298A1 (en) * 2007-03-08 2008-09-12 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
CA2681060A1 (en) * 2007-03-26 2008-10-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
WO2008132746A1 (en) * 2007-05-01 2008-11-06 Chemagis Ltd. Novel isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates
WO2009007946A1 (en) * 2007-07-09 2009-01-15 Chemagis Ltd. Process for producing cisatracurium and associated intermediates
CA2685491A1 (en) * 2007-05-01 2008-11-06 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
WO2008155752A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
AU2008320380A1 (en) * 2007-10-29 2009-05-07 Chemagis Ltd. Novel R,R'-atracurium salts
EP2283005A4 (en) * 2008-05-01 2011-08-31 Chemagis Ltd CISATRACURIUM DERIVATIVES, PREPARATION AND USES THEREOF
WO2010107488A1 (en) * 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
US9156826B2 (en) 2012-06-29 2015-10-13 Cornell University Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
WO2014210369A2 (en) * 2013-06-28 2014-12-31 Cornell University Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108375644B (zh) * 2016-12-07 2021-11-30 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂中间体的分析方法
CN110776481B (zh) 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
CN108727248B (zh) 2018-07-25 2021-05-25 四川大学华西医院 一类双季铵化合物及其制备方法和用途
WO2021115413A1 (zh) * 2019-12-11 2021-06-17 江苏恒瑞医药股份有限公司 神经肌肉阻滞剂及其制备方法
US20230381192A1 (en) 2020-10-17 2023-11-30 Cornell University Methods for controlling and predicting recovery after nmba administration

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
US4036959A (en) * 1974-10-29 1977-07-19 Millmaster Onyx Corporation Microbiocidal capped polymers
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
US4039682A (en) * 1976-03-29 1977-08-02 Baxter Travenol Laboratories, Inc. Method and composition for relief of back pain
US4192877A (en) * 1977-08-01 1980-03-11 Massachusetts General Hospital Neuromuscular blocking agents
FI782363A7 (fi) * 1977-08-01 1979-02-02 Massachusetts Gen Hospital Nerv-muskel-blockeringsaemne
US4235906A (en) * 1978-07-21 1980-11-25 Massachusetts General Hospital Bis-isoquinolinium compounds, compositions and methods of use
EP0008824B1 (en) 1978-09-05 1982-04-28 Akzo N.V. Acid addition salts of 16-beta-monoquaternary ammonium derivatives of 2-beta, 16-beta-bis-piperidino-androstanes and pharmaceutical preparations containing same
US4491665A (en) * 1979-10-19 1985-01-01 Burroughs Wellcome Co. Method of preparing isomers of bis isoquinolinium compounds
US4556712A (en) * 1981-05-20 1985-12-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines
US4727146A (en) * 1980-07-03 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction
US4701460A (en) * 1980-12-17 1987-10-20 Burroughs Wellcome Co. Long duration neuromuscular blocking agents
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
BG38182A1 (en) * 1983-06-21 1985-11-15 Ivanova Tocolytic means
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
DE3436179A1 (de) * 1984-10-03 1986-04-10 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur herstellung optisch aktiver amine
GB8518634D0 (en) * 1985-07-23 1985-08-29 Smithkline Beckman Corp Chemical compounds
US5453510A (en) * 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
DE4135710A1 (de) * 1991-10-30 1993-05-06 Basf Ag, 6700 Ludwigshafen, De Cyclische ammoniumverbindungen und ihre verwendung als glanzmittel fuer waessrig-saure galvanische nickelbaeder
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines
US5739170A (en) * 1992-09-11 1998-04-14 The Regents Of The University Of California Inhibitors of metazoan parasite proteases
US5684154A (en) * 1996-02-16 1997-11-04 Abbott Laboratories Process for the preparation and isolation of atracurium besylate
MY121316A (en) 1997-03-25 2006-01-28 Cornell Res Foundation Inc Substituted isoquinolines as ultra short acting neuromuscular blockers
AU2387997A (en) * 1997-04-18 1998-11-13 Klinge Pharma Gmbh Stabilized medicaments containing cysteinyl derivatives
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US7037489B2 (en) * 1999-12-21 2006-05-02 Kanebo Cosmetics, Inc. Skin external agents and drugs
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US7763263B2 (en) * 2000-03-30 2010-07-27 Kao Corporation Skin external agents and drugs
JPWO2002051836A1 (ja) * 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE50213989D1 (de) * 2001-01-12 2009-12-24 Biogen Idec Internat Gmbh Verwendung von fumarsäureamiden
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
EP1676580A4 (en) * 2003-08-12 2010-07-28 Nippon Zoki Pharmaceutical Co PREPARATION HAVING A HIGH CONCENTRATION OF GLYCYRRHIZINE
WO2005041960A2 (en) * 2003-10-28 2005-05-12 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof
US8197808B2 (en) * 2005-12-27 2012-06-12 Ramot At Tel-Aviv University Ltd. Stable enzymatic preparations and methods of use thereof
EP2101772B1 (en) 2006-12-06 2012-04-25 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
WO2010107488A1 (en) * 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) * 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection

Also Published As

Publication number Publication date
US8148398B2 (en) 2012-04-03
AU2007328210A2 (en) 2011-06-09
JP2010511715A (ja) 2010-04-15
EP2101772B1 (en) 2012-04-25
CN101588803B (zh) 2013-03-20
EP2101772A4 (en) 2010-12-01
EP2101772A1 (en) 2009-09-23
US20080139482A1 (en) 2008-06-12
CN101588803A (zh) 2009-11-25
CA2671904C (en) 2012-07-03
CA2671904A1 (en) 2008-06-12
JP5213137B2 (ja) 2013-06-19
AU2007328210B2 (en) 2012-11-22
WO2008070121A1 (en) 2008-06-12
AU2007328210A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
ATE469895T1 (de) Cgrp-rezeptorantagonisten
GB2453058A (en) Kinase antagonists
ATE500250T1 (de) Azetidinverbindungen als orexin-rezeptor- antagonisten
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
CY1115713T1 (el) Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
MY151191A (en) Novel antibodies
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
EA200702643A1 (ru) Антитела, связывающие tweak
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
BRPI0605921A2 (pt) compostos orgánicos
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
TW200732349A (en) Anti-OX40L antibodies and methods using same
CY1111811T1 (el) Μεθοδοι ms για την αξιολογηση γλυκανων
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
UA99292C2 (uk) Антитіло, яке специфічно зв'язується з нейропіліном-2в (nrp2b)
DK1761497T3 (da) Azadecalinglucocorticoidreceptormodulatorer
EA200900767A1 (ru) Антагонистические антитела против ephb3
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201000258A1 (ru) Новые гербициды